NR4A1 and breast cancer: Unlike hormone receptor positive or HER2/neu positive breast cancer (BC), there is no effective targeted therapy for treatment of TNBC with the exception of those with germline BRCA1/2 mutations [1–5] or programmed death ligand-1 (PD-L1)-expressing TNBCs [6–8].